pravastatin has been researched along with Heart Failure in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bin, J; Cao, S; Liao, Y; Wang, X; Xu, D; Zeng, Z | 1 |
| Blankenberg, S; Colquhoun, D; Hunt, D; Keech, AC; Mann, K; Nestel, P; Simes, J; Stewart, R; Sullivan, D; Thompson, P; Tonkin, A; West, M; White, HD | 1 |
| Blankenberg, S; Colquhoun, D; Funke-Kaiser, A; Hunt, D; Mann, K; Simes, J; Sullivan, D; Sydow, K; Tonkin, AM; West, M; White, H; Zeller, T | 1 |
| Seo, HS | 1 |
| Baek, SH; Cho, HJ; Jeon, HK; Kang, SM; Kim, HY; Lee, HY; Shin, JH | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Anand, IS; Apple, FS; Cannon, CM; Christenson, RH; Clopton, P; Daniels, LB; deFilippi, C; Diercks, DB; Hogan, CJ; Hollander, JE; Jaffe, AS; Limkakeng, A; Maisel, AS; Marston, NA; McCord, J; Mueller, C; Nagurney, J; Neath, SX; Nowak, RM; Peacock, WF; Schreiber, D; Shah, KS; Vilke, GM; Wu, AH | 1 |
| Cooper, LS; Dunning, A; Fiuzat, M; Fleg, JL; Kelly, JP; Keteyian, SJ; Kitzman, DW; Kraus, WE; Leifer, ES; Mentz, RJ; O'Connor, CM; Pina, IL; Schulte, PJ; Whellan, DJ | 1 |
| Ford, JS; Tayek, JA | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Takashima, S; Zhao, H | 1 |
| Strandberg, TE | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Saito, Y; Sasaki, N; Shinomiya, M; Shirai, K; Yoshida, S | 1 |
| Bosmans, JM; Bridts, CH; Conraads, VM; De Clerck, LS; Schuerwegh, AJ; Stevens, WJ; Vrints, CJ; Wuyts, FL | 1 |
| Ichihara, G; Ichihara, S; Kawanishi, S; Nagata, K; Noda, A; Obata, K; Oikawa, S; Xu, J; Yamada, Y; Yokota, M | 1 |
| Antikainen, M; Ehnholm, C; Hedman, M; Holmberg, C; Jauhiainen, M; Jokinen, E; Pahlman, R; Sundvall, J; Syvänne, M | 1 |
| Chen, F; Han, ZH; Hu, R; Jiang, TY; Ren, XJ; Wang, CM; Wu, XS; Zhang, WD; Zhang, XX; Zhao, H | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Carlsen, SM; Fougner, KJ | 1 |
| Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT | 1 |
1 review(s) available for pravastatin and Heart Failure
| Article | Year |
|---|---|
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
14 trial(s) available for pravastatin and Heart Failure
| Article | Year |
|---|---|
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic
Topics: Adult; Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Coronary Disease; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Pravastatin; Risk Assessment; Stroke; Troponin I | 2014 |
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Topics: Adrenomedullin; Adult; Aged; Biomarkers; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Pravastatin; Predictive Value of Tests; Prognosis; Protein Precursors; Recurrence; Risk Assessment | 2014 |
Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
Topics: Aged; Biomarkers; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Prospective Studies; Quinolines; Recovery of Function; Republic of Korea; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial.
Topics: Acute Disease; Adrenomedullin; Aged; Biomarkers; Chest Pain; Emergency Service, Hospital; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Precursors; Risk Assessment; Risk Factors; Severity of Illness Index | 2015 |
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.
Topics: Aged; Atorvastatin; Exercise Therapy; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Oxygen Consumption; Pravastatin; Quality of Life; Simvastatin; Stroke Volume; Treatment Outcome; Walk Test | 2016 |
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticholesteremic Agents; Arrhythmias, Cardiac; Cause of Death; Female; Follow-Up Studies; Heart Failure; Humans; Hypercholesterolemia; Incidence; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Prospective Studies; Risk Factors | 2002 |
Effect of short-term treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and nonischemic disease.
Topics: Aged; Case-Control Studies; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Probability; Prospective Studies; Receptors, Cytokine; Sensitivity and Specificity; Treatment Outcome | 2005 |
Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy.
Topics: Adolescent; Anticholesteremic Agents; Biomarkers; Child; Child, Preschool; Cholesterol, HDL; Colorimetry; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Graft Rejection; Heart Failure; Heart Transplantation; Humans; Infant; Male; Postoperative Complications; Pravastatin; Prospective Studies; Treatment Outcome; Ultracentrifugation | 2007 |
[The primary observation on the effect of pravastatin to non-ischemic heart failure].
Topics: Adult; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pravastatin; Ventricular Function, Left | 2007 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; Databases, Factual; Double-Blind Method; Doxazosin; Female; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Assessment; Survival Rate; Treatment Outcome; United States | 2001 |
9 other study(ies) available for pravastatin and Heart Failure
| Article | Year |
|---|---|
Pravastatin slows the progression of heart failure by inhibiting the c-Jun N-terminal kinase-mediated intrinsic apoptotic signaling pathway.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cardiotonic Agents; Caspase 12; Cells, Cultured; Gene Expression; Heart Failure; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Pravastatin; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2013 |
Appropriate candidates for statin use in heart failure.
Topics: Cholesterol, LDL; Dyslipidemias; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Quinolines | 2014 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Cardiomegaly; Endoplasmic Reticulum; Fibrosis; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Molecular Chaperones; Myocardium; Myocytes, Cardiac; Pravastatin; Signal Transduction; Stress, Physiological; Tumor Necrosis Factor-alpha; Ventricular Pressure; Ventricular Remodeling | 2008 |
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
Topics: Animals; Anticholesteremic Agents; Atrial Natriuretic Factor; Collagen; Disease Progression; Fibronectins; Glutathione; Heart Failure; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Models, Animal; Myocardium; Myosin Heavy Chains; NADPH Oxidases; Natriuretic Peptide, Brain; Oxidative Stress; Pravastatin; Rats; Rats, Inbred Dahl; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium Chloride, Dietary; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2006 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
[Statin therapy, Q10 and heart failure. Is there any difference between statins?].
Topics: Anticholesteremic Agents; Coenzymes; Heart Failure; Humans; Lovastatin; Pravastatin; Ubiquinone | 1994 |